AMPH vs. EVO, CPRX, AGIO, KROS, GLPG, DCPH, AMRX, RCKT, SNDX, and ZLAB
Should you be buying Amphastar Pharmaceuticals stock or one of its competitors? The main competitors of Amphastar Pharmaceuticals include Evotec (EVO), Catalyst Pharmaceuticals (CPRX), Agios Pharmaceuticals (AGIO), Keros Therapeutics (KROS), Galapagos (GLPG), Deciphera Pharmaceuticals (DCPH), Amneal Pharmaceuticals (AMRX), Rocket Pharmaceuticals (RCKT), Syndax Pharmaceuticals (SNDX), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical preparations" industry.
Evotec (NASDAQ:EVO) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations and institutional ownership.
Amphastar Pharmaceuticals received 383 more outperform votes than Evotec when rated by MarketBeat users. However, 75.00% of users gave Evotec an outperform vote while only 66.78% of users gave Amphastar Pharmaceuticals an outperform vote.
5.8% of Evotec shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 1.0% of Evotec shares are held by company insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Amphastar Pharmaceuticals has a net margin of 22.88% compared to Amphastar Pharmaceuticals' net margin of 0.00%. Evotec's return on equity of 29.17% beat Amphastar Pharmaceuticals' return on equity.
Evotec presently has a consensus target price of $11.00, indicating a potential upside of 109.92%. Amphastar Pharmaceuticals has a consensus target price of $66.00, indicating a potential upside of 51.86%. Given Amphastar Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Evotec is more favorable than Amphastar Pharmaceuticals.
In the previous week, Amphastar Pharmaceuticals had 3 more articles in the media than Evotec. MarketBeat recorded 7 mentions for Amphastar Pharmaceuticals and 4 mentions for Evotec. Amphastar Pharmaceuticals' average media sentiment score of 0.55 beat Evotec's score of 0.42 indicating that Evotec is being referred to more favorably in the media.
Evotec has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.
Amphastar Pharmaceuticals has lower revenue, but higher earnings than Evotec.
Summary
Amphastar Pharmaceuticals beats Evotec on 9 of the 16 factors compared between the two stocks.
Get Amphastar Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amphastar Pharmaceuticals Competitors List
Related Companies and Tools
